Tumor protection by IL-7 secreting whole cell vaccine is merely mediated by NK1.1-positive cells

Journal of Immunotherapy

Volumn 35, Issue 2, 2012, Pages 125-130

  Schroten, Caroline ^a,c   Scheffer, Reinilde ^a   Boon, Louis ^b   De Ridder, Corrina M A ^a   Bangma, Chris H ^a   Kraaij, Robert ^a  

^a JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^b BIOCEROS   (Netherlands)

^c NONE   (Netherlands)

Author keywords

interleukin 7; MPR model; NK1.1 cells; prostate cancer

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 7; TUMOR CELL VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER SURVIVAL; CONTROLLED STUDY; IMMUNE RESPONSE; MALE; METASTASIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 84856822256     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318242514b     Document Type: Article

References (19)

1. Ferraro B, Cisper NJ, Talbott KT, et al. Co-delivery of PSA and PSMA DNA vaccines with electroporation induces potent immune responses. Hum Vaccin. 2011;7:120-127.
2. Krupa M, Canamero M, Gomez CE, et al. Immunization with recombinant DNA and modified vaccinia virus Ankara (MVA) vectors delivering PSCA and STEAP1 antigens inhibits prostate cancer progression. Vaccine. 2011;29:1504-1513.
3. Jahnisch H, Fussel S, Kiessling A, et al. Dendritic cell-based immunotherapy for prostate cancer. Clin Dev Immunol. 2010; 2010:517493.
4. Anassi E, Ndefo UA. Sipuleucel-T (provenge) injection: The first immunotherapy agent (vaccine) for hormone-refractory prostate cancer. P T. 2011;36:197-202.
5. Li B, VanRoey MJ, Jooss K. Recombinant IL-7 enhances the potency of GM-CSF-secreting tumor cell immunotherapy. Clin Immunol. 2007;123:155-165. (Pubitemid 46590070)
6. Schroten-Loef C, de Ridder CM, Reneman S, et al. A prostate cancer vaccine comprising whole cells secreting IL-7, effective against subcutaneous challenge, requires local GM-CSF for intraprostatic efficacy. Cancer Immunol Immunother. 2009;58:373-381.
7. Lee G, Namen AE, Gillis S, et al. Recombinant interleukin-7 supports the growth of normal B lymphocyte precursors. Curr Top Microbiol Immunol. 1988;141:16-18.
8. Bradley LM, Haynes L, Swain SL. IL-7: Maintaining T-cell memory and achieving homeostasis. Trends Immunol. 2005; 26:172-176. (Pubitemid 40312525)
9. Vicari AP, Herbelin A, Leite-de-Moraes MC, et al. NK1.1+ T cells from IL-7-deficient mice have a normal distribution and selection but exhibit impaired cytokine production. Int Immunol. 1996;8:1759-1766. (Pubitemid 26382147)
10. Di Carlo E, D'Antuono T, Pompa P, et al. The lack of epithelial interleukin-7 and BAFF/BLyS gene expression in prostate cancer as a possible mechanism of tumor escape from immunosurveillance. Clin Cancer Res. 2009;15:2979-2987.
11. Sorrentino C, Musiani P, Pompa P, et al. Androgen deprivation boosts prostatic infiltration of cytotoxic and regulatory T lymphocytes and has no effect on disease-free survival in prostate cancer patients. Clin Cancer Res. 2011; 17:1571-1581.
12. Hull GW, McCurdy MA, Nasu Y, et al. Prostate cancer gene therapy: Comparison of adenovirus-mediated expression of interleukin 12 with interleukin 12 plus B7-1 for in situ gene therapy and gene-modified, cell-based vaccines. Clin Cancer Res. 2000;6:4101-4109.
13. Hall SJ, Thompson TC. Spontaneous but not experimental metastatic activities differentiate primary tumor-derived vs metastasis-derived mouse prostate cancer cell lines. Clin Exp Metastasis. 1997;15:630-638. (Pubitemid 27435744)
14. Todryk SM, Birchall LJ, Erlich R, et al. Efficacy of cytokine gene transfection may differ for autologous and allogeneic tumour cell vaccines. Immunology. 2001;102: 190-198. (Pubitemid 32217511)
15. Kraaij R, van Weerden WM, de Ridder CM, et al. Validation of transrectal ultrasonographic volumetry for orthotopic prostate tumours in mice. Lab Anim. 2002;36:165-172. (Pubitemid 34311410)
16. Rembrink K, Romijn JC, van der Kwast TH, et al. Orthotopic implantation of human prostate cancer cell lines: A clinically relevant animal model for metastatic prostate cancer. Prostate. 1997;31:168-174. (Pubitemid 27225200)
17. Limpens J, Schroder FH, de Ridder CM, et al. Combined lycopene and vitamin E treatment suppresses the growth of PC-346C human prostate cancer cells in nude mice. J Nutr. 2006;136:1287-1293.
18. Podoba JE, Stevenson MM. CD4+ and CD8+ T lymphocytes both contribute to acquired immunity to blood-stage Plasmodium chabaudi AS. Infect Immun. 1991;59:51-58.
19. Kohm AP, McMahon JS, Podojil JR, et al. Cutting Edge: Anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells. J Immunol. 2006;176:3301-3305. (Pubitemid 43363974)